FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... November 3, 2025 EMA Starts Review of Rucaparib May 19, 2022 Load more HOT NEWS Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies Cancer in My Community: Expanding Genetic Testing in Thailand Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results
